BOSTON (CBS.MW) -- The biotechnology sector sold off for a second ... to close at $8.22. Ariad's slide began Monday, following the release of fairly positive clinical news on its anti-tumor ...

VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since ... are expected in Q4'23. Vir Biotechnology (NASDAQ:VIR) is a biotech ...

The normally high-flying biotechnology sector is scuffling this ... SBIO's weighting methodology that indicate the fund's recent slide could be a buying opportunity for bold investors.

On the first day of the biggest annual conference for the life sciences industry — the event for which companies try and put their best foot forward — biotechnology stocks were hitting a low ...